PPARGC1A and nonpapillary renal cell carcinoma: FTO partially promoted the anti-tumor properties of ccRCC by decreasing m6A levels of PPARγ coactivator (PGC)‐1α mRNA transcripts and therefore increasing PGC-1α expression[40].